LifeTime™ is a clinical-stage pharmaceutical company focused on that focuses on "fast tracked" small molecules designed to treat and prevent the recurrence of life-threatening chronic infectious and malignant diseases. It is a company focused on the clinical development and commercialization of promising new compounds for human therapeutics. Its lead compound is Beta LT™, an anti-cancer immune stimulant, which is currently in Phase I/II trials in Canada and waiting for Phase I/II start-up in America. While current approaches generally cause remissions, the few cells (or viruses) not killed by current therapy generally multiply, ultimately killing the person. To prevent this, they specialize in developing novel, to date completely non-toxic, long-term therapeutic products.